🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the effort against superbug strains of the bacteria, according to health experts.

A Global Challenge

Gonorrhoea infections are escalating around the world, with estimates suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Outcomes and Global Access

Based on findings released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Clinicians on the front lines have voiced positive views. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for managing the epidemic. This is deemed crucial to alleviate the strain of the infection for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.